Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14182609 | 0.91 | HDAC1 (0.53) | HDAC1TRPV1LCKKCNH2 | |
| SCHEMBL13439099 | 0.87 | HDAC1 (0.73) | HDAC1KCNH2 | |
| SCHEMBL12772655 | 0.86 | HDAC1 (0.54) | HDAC1TRPV1LCKKCNH2 | |
| SCHEMBL13462579 | 0.86 | HDAC1 (0.52) | HDAC1TRPV1KCNH2 | |
| SCHEMBL3603571 | 0.86 | HDAC1 (0.60) | HDAC1TRPV1KCNH2 | |
| SCHEMBL8263661 | 0.85 | HDAC1 (0.76) | HDAC1KCNH2 | |
| SCHEMBL13439106 | 0.84 | HDAC1 (0.77) | HDAC1KCNH2 | |
| SCHEMBL8242955 | 0.82 | HDAC1 (0.52) | HDAC1TRPV1LCKKCNH2 | |
| SCHEMBL1064323 | 0.80 | HDAC1 (0.53) | HDAC1LCK | |
| SCHEMBL30944730 | 0.80 | HDAC1 (0.53) | HDAC1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | disclosed |
| WO-2006075160-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885TRPV1 2925/4885LCK 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.